Evaluation of HER-2 expression in breast cancer using image analysis incorporating automatic feature recognition

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 20007-20007
Author(s):  
C. Murray ◽  
J. Maddison ◽  
C. Anderson ◽  
D. Challender ◽  
S. Palmer ◽  
...  

20007 The currently favoured method for evaluation of HER-2 in routine clinical practice and research studies is immunohistochemistry (IHC). As standardised scoring of protein expression, using a scale of 0 - 3+, generates a significant number of false positives, fluorescent in situ hybridisation (FISH) is used to confirm the presence of gene amplification. Both techniques are laborious, and in the case of by-eye scoring of IHC, semi-quantitative at best. We have developed a high-throughput platform for the quantitative analysis of immunostained slides, based on fast, high-resolution scanning followed by analysis of digitised images (IA) using proprietary software, and in this study compared results obtained using this platform with those obtained using conventional methods. Archival sections of primary breast cancers collected at Nottingham City Hospital in 2004 and 2005 were stained for HER-2 (Herceptest, Dako), and evaluated by eye. Equal numbers of slides from scoring categories 0–3+ were then selected for further image analysis. The digitised images were subjected to automatic delineation to define areas of tumour parenchyma, and these areas further analysed using colour segmentation. Between 100 and 2000 fields were quantified on each section. Staining was expressed as a product of field fraction of coloured pixels and optical density. The results of IA demonstrate a continuum of staining values over the four conventional by-eye categories, with a non-linear correlation to by-eye scores. Inter-sample variation was greatest in the 3+ category, although the mean was much higher than that of the 2+ samples. The 2+ samples showed some variation, with several values not rising above baseline. To further investigate the relationship between FISH scores and IA results in the 2+ category, we analysed an additional set of slides in this group, and found a correlation between FISH and automated IA scores. We conclude that automated image analysis is sensitive to small differences in protein expression, has a wide dynamic range, and provides data superior to conventional by-eye scoring. In undecided cases HER-2 protein expression correlates with FISH data; therefore ultimately IA of HER-2 protein expression alone may provide a basis for clinical decisions. [Table: see text]

2020 ◽  
Vol 68 (9) ◽  
pp. 635-643 ◽  
Author(s):  
Maren C. Podszun ◽  
Joon-Yong Chung ◽  
Kris Ylaya ◽  
David E. Kleiner ◽  
Stephen M. Hewitt ◽  
...  

Lipid peroxidation is a common feature of liver diseases, especially non-alcoholic fatty liver disease (NAFLD). There are limited validated tools to study intra-hepatic lipid peroxidation, especially for small specimen. We developed a semi-quantitative, fully automated immunohistochemistry assay for the detection of 4-hydroxynoneal (4-HNE) protein adducts, a marker of lipid peroxidation, for adaptation to clinical diagnostics and research. We used Hep G2 cells treated with 4-HNE to validate specificity, sensitivity, and dynamic range of the antibody. Staining and semi-quantitative automated readout were confirmed in human needle-biopsy liver samples from subjects with NAFLD and normal liver histology. The ability to detect changes in lipid peroxidation was tested in paired liver biopsies from NAFLD subjects, obtained before and after 4 weeks of treatment with the antioxidant vitamin E (ClinicalTrials.gov NCT01792115, n=21). The cellular calibrator was linear and NAFLD patients had significantly higher levels of 4-HNE adducts compared to controls ( p=0.02). Vitamin E treatment significantly decreased 4-HNE ( p=0.0002). Our findings demonstrate that 4-HNE quantification by immunohistochemistry and automated image analysis is feasible and able to detect changes in hepatic lipid peroxidation in clinical trials. This method can be applied to archival and fresh samples and should be considered for use in assessing NAFLD histology.


IEEE Access ◽  
2020 ◽  
pp. 1-1
Author(s):  
Min Feng ◽  
Jie Chen ◽  
Xuhui Xiang ◽  
Yang Deng ◽  
Yanyan Zhou ◽  
...  

1999 ◽  
Vol 17 (7) ◽  
pp. 1983-1983 ◽  
Author(s):  
Timothy W. Jacobs ◽  
Allen M. Gown ◽  
Hadi Yaziji ◽  
Melissa J. Barnes ◽  
Stuart J. Schnitt

PURPOSE: To evaluate the specificity of the HercepTest for Immunoenzymatic Staining (Dako Corp, Carpinteria, CA) for determining HER-2/neu protein expression in breast cancer. MATERIALS AND METHODS: Forty-eight invasive breast cancers previously found to be HER-2/neu–negative by two different immunohistochemical (IHC) assays and not amplified for the HER-2/neu gene by fluorescence in situ hybridization were studied using the HercepTest kit. HercepTest was performed according to the manufacturer's guidelines, and the results were scored on a 0 to 3+ scale using the United States Food and Drug Administration (FDA)–approved grading system. In this system, cases scored as 2+ or 3+ are considered HER-2/neu–positive. RESULTS: Among these 48 cases, the IHC score using the FDA-approved scoring system was 0 in four cases (8.3%), 1+ in 16 (33.3%), 2+ in 21 (43.8%), and 3+ in seven (14.6%). Therefore, 58.4% of these cases were categorized as HER-2/neu–positive, and the specificity of the HercepTest kit for HER-2/neu expression was 41.6%. However, with the use of a modified scoring system that took into account the level of staining of nonneoplastic epithelium, the specificity increased to 93.2%. CONCLUSION: Our results indicate that the HercepTest kit, when used in accordance with the manufacturer's guidelines and the FDA-approved scoring system, results in a large proportion of breast cancers being categorized as positive for HER-2/neu protein expression and that many of these seem to be false-positives. Consideration of the level of staining of nonneoplastic epithelium resulted in improved specificity. The current FDA-approved scoring system for HercepTest results should be reevaluated before its widespread use in clinical practice.


2012 ◽  
Vol 43 (11) ◽  
pp. 2053-2061 ◽  
Author(s):  
Nicholas P. Tobin ◽  
Katja L. Lundgren ◽  
Catherine Conway ◽  
Lola Anagnostaki ◽  
Sean Costello ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document